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Abstract
Objectives To determine the diagnostic accuracy of surveil-
lance mammography for detecting ipsilateral breast tumour
recurrence and metachronous contralateral breast cancer in
women previously treated for primary breast cancer.
Methods A systematic review of surveillance mammography
compared with ultrasound, magnetic resonance imaging
(MRI), specialist-led clinical examination or unstructured
primary care follow-up, using histopathological assessment
for test positives and follow-up for test negatives as the
reference standard.
Results Nine studies met our inclusion criteria. V ariations in
study comparisons precluded meta-analysis. For routine
ipsilateral breast tumour detection, surveillance mammog-
raphy sensitivity ranged from 64–67% and specificity
ranged from 85–97%. For MRI, sensitivity ranged from
86–100% and specificity was 93%. For non-routine
ipsilateral breast tumour detection, sensitivity and specific-
ity for surveillance mammography ranged from 50–83%
and 57–75% and for MRI 93–100% and 88–96%. For
routine metachronous contralateral breast cancer detection,
one study reported sensitivity of 67% and specificity of
50% for both surveillance mammography and MRI.
Conclusion Although mammography is associated with high
sensitivity and specificity, MRI is the most accurate test for
detecting ipsilateral breast tumour recurrence and metachro-
nous contralateral breast cancer in women previously treated
for primary breast cancer. Results should be interpreted with
caution because of the limited evidence base.
Key Points
￿ Surveillance mammography is associated with high
sensitivity and specificity
￿ Findings suggest that MRI is the most accurate test for
detecting further breast cancer
￿ Robust conclusions cannot be made due to the limited
evidence base
￿ Further research comparing surveillance mammography
and other diagnostic tests is required
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Introduction
In women previously treated for breast cancer, surveillance
mammography is useful for early detection of tumour
recurrence, or for confirming the absence of recurrent
cancer, and for the early detection of contralateral cancers.
Although published figures vary, it has been estimated that
approximately 50% of local recurrences in the breast
following breast conservation surgery will be detected by
mammography, with the remainder being detected by
clinical examination or reported by the patient [1–4].
Recurrent tumours detected by mammography are generally
smaller and less invasive than those found on clinical
examination [2, 4]. Lu and colleagues [5] recently
conducted a systematic review to determine the impact of
early detection of isolated loco-regional and contralateral
recurrence on survival. The authors reported better overall
survival for recurrences detected by mammography or in
asymptomatic patients, with an absolute reduction in
mortality of 17–28% if all breast cancer recurrences are
detected early.
While tumour recurrence displays similar mammographic
features to the primary lesion [4], interpretation of the
surveillance mammogram is made more difficult by surgical
scarring and changes to breast density caused by primary
treatment. For example, following surgery and/or radiother-
apy, detectable abnormalities on mammography may include
the presence of old haematoma, scar formation, fat necrosis,
skin thickening, increased soft tissue density in the breast
and microcalcifications. Approximately 10% of palpable
tumours are not clearly visible on mammography and require
additional imaging techniques for their demonstration.
Surveillance mammography is therefore also associated with
the possibility of false-positive results, which then require
further investigations that are unnecessary and have a
negative impact on a woman’s quality of life.
We conducted a National Institute for Health Research
Health Technology Assessment programme funded project
(NIHR HTA Project 07/47/01) to examine the clinical
effectiveness and cost-effectiveness of different surveillance
mammography regimens after the treatment of primary
breast cancer in the UK in primary and secondary care
settings. The work comprised: a survey of UK breast
surgeons and radiologists, a series of systematic reviews
(test performance review presented here), and statistical and
economic modelling to determine the effectiveness, cost
consequences and cost utility of differing surveillance
regimens.
T h ep r i m a r yo b j e c t i v eo ft h i ss y s t e m a t i cr e v i e ww a s
to determine the test performance of surveillance
mammography, alone or in combination with other tests,
in detecting ipsilateral breast tumour recurrence and/or
metachronous contralateral breast cancer in women
undergoing routine surveillance. Our secondary objec-
tive was to compare surveillance mammography perfor-
mance with alternative tests, alone or in combination, in
women with a previous diagnostic test result indicating
suspected ipsilateral breast tumour recurrence and/or
metachronous contralateral breast cancer (referred to
subsequently as non-routine surveillance).
Materials and methods
We developed and followed a structured protocol. We
considered randomised controlled trials of surveillance
mammography and diagnostic consecutive cohort studies
of surveillance mammography or other comparator tests,
involving women previously treated for primary breast
cancer without detectable metastatic disease at the time of
presentation for their initial treatment. We also considered
indirect (between-study) comparisons by comparing cohort
studies analysing results of at least 100 women who
received surveillance mammography, or a comparator test,
or a combination of tests, with the reference standard test in
the same population. We excluded case reports and studies
investigating technical aspects of a test. Comparator tests
included ultrasound, magnetic resonance imaging (MRI),
specialist-led clinical examination and unstructured primary
care follow-up (defined as absence of formal routine
secondary care follow-up, which may or may not involve
mammography). The reference standard was histopatholog-
ical assessment for test positives and a period of follow-up
for test negatives.
We chose to include studies assessing test performance
for routine and non-routine surveillance patients. Adjunct
tests are part of breast cancer surveillance management and
the performance of diagnostic tests used for this purpose is
relevant to our population of interest. The accuracy of non-
Eur Radiol (2011) 21:2484–2491 2485routine adjunct imaging tests may differ from the accuracy
of first-line surveillance tests as the test operator is primed
to evaluate a suspicious finding in the non-routine
surveillance patient. It is unclear what effect this has on
test accuracy but it is likely to focus attention on a
particular area of the breast and may conceivably increase
the diagnostic test sensitivity. Consequently, we have not
attempted to mix or compare the performance of tests used
for these different purposes. Similarly, because of anatom-
ical differences between a “treated” and an “untreated”
breast (due to treatment effects) it was inappropriate to
combine data on test performance for the detection of
ipsilateral breast tumour recurrence and metachronous
contralateral breast cancer.
The following types of outcome were considered:
& Test performance in diagnosing ipsilateral breast tumour
recurrence in women undergoing routine surveillance
& Test performance in diagnosing ipsilateral breast
tumour recurrence in women undergoing non-routine
surveillance
& Test performance in diagnosing metachronous contra-
lateral breast cancer in women undergoing routine
surveillance
& Test performance in diagnosing metachronous contra-
lateral breast cancer in women undergoing non-routine
surveillance
To be considered for inclusion, the studies had to report the
absolute numbers of true-positives, false-positives, false-
negatives and true-negatives, or provide information allow-
ing their calculation, and report a per-patient analysis.
In studies reporting the above outcomes, we planned to
record the following additional outcomes, if stated:
& Adverse effects (defined as physical harms) of mam-
mography and other tests
& Acceptability of the tests
& Reliability of the tests
& Radiological/operator expertise (who conducts the test
and previous experience)
& Interpretability/readability of the tests
Major electronic databases were searched using sensitive
search strategies to identify diagnostic studies of surveil-
lance mammography, MRI, ultrasound or clinical follow-
up. Searches were conducted from 1990 to March 2009 and
were restricted to the English language. Conference
abstracts were not included. The following databases were
searched for primary studies: Medline, Medline In process,
Embase, Biosis, Science Citation Index, Cancerlit, while
Medion, the Cochrane Database of Systematic Reviews
(CDSR), Database of Reviews of Effects (DARE) and the
HTA Database were searched for reports of evidence
syntheses. Reports of ongoing and recently completed trials
were sought from Current Controlled Trials, Clinical Trials,
WHO International Clinical Trials Registry Platform, NCI
Clinical Trials Database, NRR Archive and NIHR Portfolio
Database. In addition, relevant websites were searched and
the reference lists of all included studies were scanned for
additional reports. Full details of the search strategies used
are available from the authors or the full study report,
currently in press (“The clinical effectiveness and cost-
effectiveness of different surveillance mammography regi-
mens after the treatment of primary breast cancer.” by
Robertson et al. accepted for publication in Health Technol
Assess 2011).
From an initial first screening round of titles and
abstracts we were able to exclude reports that were clearly
irrelevant to the review (e.g. did not include any of our
considered diagnostic tests). We then assessed the full text
versions of the remaining reports against our eligibility
criteria using a screening tool comprising a checklist of our
inclusion eligibility criteria, which we developed specifi-
cally for this review. One reviewer independently carried
out data extraction. A second reviewer independently
validated the data extraction. We calculated sensitivity,
specificity, positive and negative likelihood ratios and
diagnostic odds ratio for each included study.
We evaluated the quality of studies using an adapted
version of the Quality Assessment of Diagnostic Accuracy
Studies QUADAS tool [6]. Higher quality studies were
defined as those considering a representative patient
spectrum and judged to have successfully avoided partial
verification bias (whether the whole or random sample of
the population received reference standard verification),
differential verification bias (whether patients received the
same reference standard) and test review bias (whether
index and reference standard test results were interpreted
independently). Disagreement or uncertainty regarding data
extraction or quality assessment was resolved by discussion
or arbitration by a third reviewer.
Results
Figure 1 shows the flow of studies through the review.
Nine studies met our inclusion criteria. V ariation across the
included studies precluded formal meta-analysis. We there-
fore present a narrative synthesis of the results. Overall, the
nine studies enrolled 4002 participants. After exclusions,
due to eligibility or participant drop-out, the studies
included 3724 participants in their analyses. The earliest
study took place in 1995 [7] and the latest in 2009 [8]. The
earliest participant enrolment date given was 1992 [7] and
the latest was 2003 [8]. Four studies did not give any
indication of the enrolment time period [9–12]. One study
took place in Sweden [7], two in the UK [10, 11], two in
Eur Radiol (2011) 21:2484–2491 2486Germany [12, 13], two in South Korea [8, 14], one in Italy
[9] and one in France [15]. Across studies the ages of the
participants ranged from 22–82 years [8]. Most participants
were in their fifties. The median age was 53 years (inter-
quartile range 50 to 56 years). Reported follow-up of test
negatives ranged from 5 to 32 months. Table 1 provides
details of the characteristics of the included studies.
Assessment of test performance
Test performance in diagnosing ipsilateral breast tumour
recurrence
Table 2 shows test performance in detecting ipsilateral
breast tumour recurrence in patients undergoing routine
surveillance. The studies by Boné and colleagues [7] and
Drew and colleagues [10] involved a total of 188 patients
and reported the performance of surveillance mammogra-
phy, MRI and clinical examination in routine surveillance
patients. These studies reported sensitivities of 64% and
67%, and specificities of 97% and 85%, respectively, for
surveillance mammography. For MRI, the studies reported
sensitivities of 86% and 100% respectively, and for clinical
examination 50% and 89%. Boné and colleagues [7] did
not report specificity for MRI or clinical examination. The
highest reported sensitivity was for MRI, and surveillance
mammography combined with clinical examination (both
100%) while the highest specificity was for surveillance
mammography (97%). Similarly, a high specificity of 93%
was reported for MRI. The lowest reported sensitivity was
for clinical examination (50%) and the lowest specificity
was for surveillance mammography combined with clinical
examination (67%).
Table 3 shows test performance in detecting ipsilateral
breast tumour recurrence in patients undergoing non-routine
surveillance, as reported by Belli and colleagues [9], Mumtaz
and colleagues [11], Rieber and colleagues [12], and Ternier
and colleagues [15]. The studies involved a total of 156
patients. Across these studies, for surveillance mammogra-
phy the median (range) sensitivity was 71% (50% to 83%)
and specificity was 63% (57% to 75%). For MRI, the studies
by Belli and colleagues [9], Mumtaz and colleagues [11]a n d
Rieber and colleagues [12], involving a total of 193 patients,
reported sensitivity of 93% and 100% (two studies) and a
median (range) specificity of 94% (88% to 96%). Belli and
colleagues [9] and Ternier and colleagues [15]r e p o r t e dt h e
test performance of ultrasound, with sensitivities of 43% and
87%, and specificities of 31% and 73% respectively, and for
clinical examination, sensitivities of 43% and 62%, and
specificities of 56% and 49% respectively. The highest
reported sensitivity (100%) and specificity (96%) was for
MRI. The lowest reported sensitivities were (43%) for both
ultrasound and clinical examination, while the lowest
specificity was for ultrasound (31%).
Test performance in diagnosing metachronous contralateral
breast cancer
Table 4 shows test performance in detecting metachronous
contralateral breast cancer in routine surveillance patients.
2061 titles/abstracts screened (after 
exclusion of reports already identified by 
effectiveness review search) 
1815 excluded
237 reports excluded: 
Required participant eligibility not met: 77 
Index/comparator test(s) not assessed for 
ipsilateral breast tumour 
recurrence/metachronous contralateral 
breast cancer detection: 49 
Required reference standard not met: 6 
Required study design not met: 67 
Required outcomes not reported: 8 
Required comparator test not met: 19 
Retained for background information: 8 
Not available: 3
9 reports included 
246 reports selected for full text 
assessment 
Fig. 1 Flow of studies through
the review process
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colleagues [13] involving a total of 202 patients, reported
67% and 91% sensitivity and 50% and 90% specificity,
respectively, for MRI. Only individual studies reported the
test performance of surveillance mammography, clinical
examination, and combinations of tests involving surveil-
lance mammography. The highest reported sensitivity
(100%) was for combined surveillance mammography,
clinical examination, ultrasound and MRI [13], while the
highest reported specificity (99%) was for combined
Table 1 Summary of characteristics of the individual diagnostic accuracy studies
Study
ID
Study
Design
Type of surveillance
and primary surgery
Index tests Comparator test Follow-up time for verifying test
negative results
Belli
2002
[9]
Direct
head-
to-
head
co-
hort
Non-routine surveillance
breast conservation
patients
MRI for local
recurrence
Surveillance mammography,
clinical examination,
ultrasound for local
recurrence
MRI and clinical examination
follow-up performed at 3 months.
All MRI test negatives underwent
cytological examination
Boné
1995
[7]
Direct
head-
to-
head
co-
hort
Routine surveillance
mastectomy patients,
all with breast
reconstruction and
implants
Surveillance
mammography
for local and
contralateral recurrence
MRI, clinical examination for
local and contralateral recurrence
Median 10 months
(range 5–18 months)
Drew
1998
[10]
Direct
head-
to-
head
co-
hort
Routine surveillance
breast conservation
patients
MRI for local
recurrence
Surveillance mammography,
clinical examination,
surveillance mammography
+clinical examination
for local recurrence
Median 341 days
(range 168–451 days)
Kim
2009
[8]
Direct
head-
to-
head
co-
hort
Routine surveillance
breast conservation
and mastectomy
patients
Adjunct ultrasound
(surveillance
mammography+
ultrasound) for
contralateral recurrence
None 1-2 years
Mumtaz
1997
[11]
Direct
head-
to-
head
co-
hort
Non-routine surveillance
breast conservation
patients
Surveillance
mammography for local
recurrence
MRI for local recurrence Median 12 months
(range 6–15 months)
Rieber
1997
[12]
Cohort Non-routine surveillance
breast conservation
patients
MRI for local
recurrence
None clinical examination, ultrasound
performed at 6 months follow-up.
Surveillance mammography
performed at 12 months’ follow-
up. In 22 patients a control MRI
was performed at intervals of 2–
16 months (mean 7.2 months)
Shin
2005
[14]
Cohort Routine surveillance
patients (primary
surgery type not
reported)
Ultrasound for local
and contralateral
recurrence
None 6 months
Ternier
2006
[15]
Direct
head-
to-
head
co-
hort
Non-routine surveillance
breast conservation
patients
Surveillance
mammography for local
recurrence
2
Clinical examination,
ultrasound for local
recurrence
6 months
Viehweg
2004
[13]
Direct
head-
to-
head
co-
hort
Routine surveillance
breast conservation
patients
MRI for contralateral
recurrence
Conventional methods (surveillance
mammography+clinical examination+
ultrasound); MRI+Conventional
methods for contralateral recurrence
12 months
1. MRI magnetic resonance imaging
2. Studyauthorsconsideredcomputedtomographyastheindextestinthisstudybutthistestwasnotconsideredasanincludedcomparatorinthisreview
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reported sensitivity (0%) was for clinical examination and
the lowest specificity was for surveillance mammography,
MRI and clinical examination (all 50%) [7].
None of the studies reported diagnostic accuracy of the
included tests for diagnosing metachronous contralateral
breast cancer in non-routine surveillance patients with a
previous suspicious test result.
Test performance in diagnosing ipsilateral breast tumour
recurrence and metachronous contralateral breast cancer
The study conducted by Shin and colleagues [14] was the
sole study reporting overall test performance for diagnosing
ipsilateral breast tumour recurrence and metachronous
contralateral breast cancer. Shin and colleagues evaluated
ultrasound in routine surveillance patients, reporting a
sensitivity of 71% and a specificity of 98%, LR+41.4, LR
− 0.3, OR 138.25 (95% CI 61.26 to 312.04).
Quality assessment
None of the studies met all of our criteria specified for
higher quality studies, although in five[8, 9, 11, 12, 15]
this was due to lack of clarity as to whether reference
standard results were interpreted without knowledge of
index test results only. It was unclear in all but one study
[14] whether the time interval between a positive test
result and the histopathological reference standard was
short enough to avoid improvement or progression of the
condition occurring in the intervening period (disease
progression bias). We are therefore uncertain of the effects
of this type of bias for positive test results in these studies.
All studies were judged to have appropriate follow-up
time intervals for confirming negative test results and were
therefore considered to be at low risk of disease
progression bias for negative test results. It was unclear
in the study conducted by Shin and colleagues [14],
however, whether all patients with negative test results
Table 2 Sensitivity, specificity, likelihood and diagnostic odds ratios for detecting ipsilateral breast tumour recurrence in routine surveillance
patients
Test Study ID Primary surgical treatment Reported
sensitivity%
Reported
specificity%
LR+ LR− DOR (95%
confidence interval)
Surveillance mammography Boné 1995[7] Mastectomy 64 97 22.2 0.4 60.3 (10.2–358.1)
Drew 1998[10] Breast conservation 67 85 4.6 0.4 11.7 (2.6–52.4)
MRI Boné 1995[7] Mastectomy 86 Not reported
Drew 1998[10] Breast conservation 100 93 14.3 IC IC
Clinical examination Boné 1995[7] Mastectomy 50 Not reported
Drew 1998[10] Breast conservation 89 76 3.7 0.2 25.4 (3.0–213.9)
Combined surveillance mammography
& clinical examination
Drew 1998[10] Breast conservation 100 67 3.0 IC IC
MRI magnetic resonance imaging, LR+Likelihood ratio of a positive test result, LR Likelihood ratio of a negative test result, DOR Diagnostic
odds ratio, IC Incalculable
Table 3 Sensitivity, specificity, likelihood ratio and diagnostic odds ratio for detecting ipsilateral breast tumour recurrence in non-routine
surveillance patients
Test Study ID Primary surgical
treatment
Reported
sensitivity%
Reported
specificity%
LR
+
LR
−
DOR (95% confidence
interval)
Surveillance mammography Belli 2002[9] Breast conservation 71 63 1.9 0.5 4.2 (2.6–52.4)
Mumtaz 1997[11] Breast conservation 50 75 2.0 0. 7 3 (0.6–14.0)
Ternier 2006[15] Breast conservation 83 57 1.9 0.3 6.3 (2.5–15.6)
Ultrasound Belli 2002[9] Breast conservation 43 31 0.6 1.8 0.3 (0.1–2.1)
Ternier 2006[15] Breast conservation 87 73 3.2 0.2 17 (6.2–46.5)
MRI Belli 2002[9] Breast conservation 100 94 16.0 IC IC
Mumtaz 1997[11] Breast conservation 93 88 7.4 0.1 91 (7.4–1126. 9)
Rieber 1997[12] Breast conservation 100 96 24.2 IC IC
Clinical examination Belli 2002[9] Breast conservation 43 56 1.0 1.0 1.0 (0.2–5.8)
Ternier 2006[15] Breast conservation 62 49 1.2 0.8 1.5 (0.7–3.4)
1. MRI magnetic resonance imaging, LR+Likelihood ratio of a positive test result, LR Likelihood ratio of a negative test result, DOR Diagnostic
odds ratio, IC Incalculable
Eur Radiol (2011) 21:2484–2491 2489received follow-up and so there is a possible risk of partial
verification bias for this study. The study by Drew and
colleages [10] was considered vulnerable to partial
verification bias as only those participants testing posi-
tively on MRI received reference standard verification.
Additional outcomes
None of the included studies reported data concerning
adverse effects, acceptability, reliability, radiological/opera-
tor expertise and interpretability/readability of the tests. We
found no discernible pattern for the histology of cancers
detected and not detected both within and between
diagnostic tests.
Discussion
Our findings should be interpreted with caution, as they are
based on only nine studies involving a total of 3724
participants. Furthermore, the study conducted by Boné and
colleagues [7] included only mastectomy patients who
underwent breast reconstruction using implants. Surveil-
lance of the chest wall and/or the reconstructed breast in
patients receiving either mastectomy alone, or mastectomy
with breast reconstruction and implants, varies according to
different health care systems and local protocols [16–18].
These comprise an increasingly relevant sub-group of
women, because of increasing rates of breast reconstruction
procedures, who might receive routine surveillance mam-
mography in the future [19]. Results from this study should
be treated as distinct from the others owing to the highly
selected patient population who, whilst representing a
subset of our considered population, differ greatly from
the wider spectrum of women who receive surveillance in
practice.
Systematic reviews of diagnostic accuracy are highly
complex and methodology in this area continues to evolve.
In terms of strengths, we believe that the methods adopted for
this review are scientifically rigorous and compatible with
current guidance in this area. A limitation was that non-
English language studies were excluded, potentially limiting
the evidence base. Of the studies included here, few evaluated
the performance of the considered tests for similar purposes.
Furthermore, even where data were available it was not
clinically appropriate to combine them, for example, because
of differences between a “treated” and an “untreated” breast.
Similarly, it was inappropriate to combine data from routine
and non-routine surveillance patients. Furthermore, no data
were reported by the included studies on other aspects such as
adverse effects or acceptability of the tests.
Results for the index and comparator tests evaluated in this
review were ascertained by subjective operator interpretation,
either by visual inspection of an image of the breast
(surveillance mammography, ultrasound and MRI) or by
clinical examination of the breast. Data on the level of operator
expertise or intra/inter-rater reliability were not reported. It is
therefore unclear whether these factors had any influence on
reported test accuracy within, and between, studies and
therefore whether any potential test operator bias exists.
None of the studies met all of our criteria specified for
higher quality studies, although they were judged to have
reasonable internal validity. All but one study [8] were
considered to include a representative sample and therefore
have good external validity.
Conclusion
Our findings suggest that MRI can be considered to have
higher diagnostic value than surveillance mammography in
women previously treated for primary breast cancer. Of the
Table 4 Test performance as measured by sensitivity, specificity, likelihood ratio and diagnostic odds ratio for detecting metachronous
contralateral breast cancer in routine surveillance patients
Test Study ID Primary surgical
treatment
Reported
Sensitivity%
Reported
Specificity%
LR
+
LR
−
DOR (95%
confidence interval)
Surveillance mammography Boné 1995[7] Mastectomy 67 50 1.3 0.7 2.0 (0.1–78.2)
MRI Boné 1995[7] Mastectomy 67 50 1.3 0.7 2.0 (0.1–78.2)
Viehweg 2004[13] Breast conservation 91 90 9.4 0.1 93.1 (11.0–786.2)
Clinical examination Boné 1995[7] Mastectomy 0 50
Combined surveillance mammography
& ultrasound
Kim 2009[8] Mastectomy 95 99 61.5 0.05 1149.2 (148.0–8937.8)
Breast conservation
Combined surveillance mammography,
clinical examination & ultrasound
Viehweg 2004[13] Breast conservation 64 84 3.9 0.4 8.9 (2.4–33.0)
Combined surveillance mammography,
clinical examination, ultrasound & MRI
Viehweg 2004[13] Breast conservation 100 89 8.9 IC IC
MRI magnetic resonance imaging, LR+Likelihood ratio of a positive test result, LR Likelihood ratio of a negative test result, DOR Diagnostic
odds ratio, CI Confidence interval, IC Incalculable
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combined with breast ultrasound could be considered the
most accurate combination of tests for detecting metachro-
nous contralateral breast cancer. However these results
should be interpreted with caution owing to the paucity of
data for all diagnostic tests available for breast cancer
surveillance. Further evidence on surveillance mammogra-
phy and other diagnostic tests in this group of women is
required in order to make a robust and informed judgement
on their relative performance. Ideally a definitive rando-
mised controlled trial should be undertaken focusing on
those women at higher risk of ipsilateral breast tumour
recurrence or metachronous contralateral breast cancer.
Such a trial might also compare more sophisticated
surveillance regimens that vary not only in terms of the
frequency of mammography or other diagnostic tests but
also in terms of the frequency and setting of clinical follow-
up. Alternatively, high-quality, direct head-to-head studies
could be undertaken comparing the diagnostic accuracy of
tests used in the surveillance population.
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